A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.

Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy, but some patients have a very indolent evolution. This heterogeneous course is related, in part, to the different biological characteristics of conventional MCL (cMCL) and the distinct subgroup of leukemic nonnodal MCL (nnMCL). Robust criteria to distinguish these MCL subtypes and additional biological parameters that influence their evolution are not well defined. We describe a novel molecular assay that reliably distinguishes cMCL and nnMCL using blood samples. We trained a 16-gene assay (L-MCL16 assay) on the NanoString platform using 19 purified leukemic samples. The locked assay was applied to an independent cohort of 70 MCL patients with leukemic presentation. The assay assigned 37% of cases to nnMCL and 56% to cMCL. nnMCL and cMCL differed in nodal presentation, lactate dehydrogenase, immunoglobulin heavy chain gene mutational status, management options, genomic complexity, and CDKN2A/ATM deletions, but the proportion with 17p/TP53 aberrations was similar in both subgroups. Sequential samples showed that assay prediction was stable over time. nnMCL had a better overall survival (OS) than cMCL (3-year OS 92% vs 69%; P = .006) from the time of diagnosis and longer time to first treatment. Genomic complexity and TP53/CDKN2A aberrations predicted for shorter OS in the entire series and cMCL, whereas only genomic complexity was associated with shorter time to first treatment and OS in nnMCL. In conclusion, the newly developed assay robustly recognizes the 2 molecular subtypes of MCL in leukemic samples. Its combination with genetic alterations improves the prognostic evaluation and may provide useful biological information for management decisions.

[1]  A. Santoro,et al.  Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study , 2019, HemaSphere.

[2]  J. Ruan.  Molecular profiling and management of mantle cell lymphoma. , 2019, Hematology. American Society of Hematology. Education Program.

[3]  L. Quintanilla‐Martinez,et al.  Highly sensitive and specific in situ hybridization assay for quantification of SOX11 mRNA in mantle cell lymphoma reveals association of TP53 mutations with negative and low SOX11 expression , 2019, Haematologica.

[4]  Wei Hu,et al.  SOX11: friend or foe in tumor prevention and carcinogenesis? , 2019, Therapeutic advances in medical oncology.

[5]  A. Zelenetz,et al.  Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma , 2019, Haematologica.

[6]  E. Campo,et al.  Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. , 2018, Blood.

[7]  Michael L. Wang,et al.  CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course , 2018, Modern Pathology.

[8]  A. Rosenwald,et al.  Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. , 2018, Blood.

[9]  J. W. Hansen,et al.  TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. , 2017, Blood.

[10]  R. Gascoyne,et al.  Observation as the initial management strategy in patients with mantle cell lymphoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  W. Wilson,et al.  Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier , 2017, Haematologica.

[12]  S. Rule,et al.  Novel agents in mantle cell lymphoma , 2017, Expert review of anticancer therapy.

[13]  L. Staudt,et al.  New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Giné,et al.  Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. , 2016, Cancer cell.

[15]  A. Rosenwald,et al.  Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Döhner,et al.  Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. , 2016, Blood.

[17]  W. Wilson,et al.  Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. , 2016, Blood.

[18]  Wentian Li,et al.  A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes , 2015, Immunologic research.

[19]  W. Klapper,et al.  High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. , 2015, Blood.

[20]  S. Ferrero,et al.  Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience , 2015, Haematologica.

[21]  C. Pott,et al.  Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network , 2015, Leukemia & lymphoma.

[22]  E. Giné,et al.  Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption , 2014, Haematologica.

[23]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[24]  W. C. Chan,et al.  High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma , 2014, Oncogene.

[25]  J. Delabie,et al.  SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study , 2014, British journal of haematology.

[26]  E. Campo,et al.  Assessment of SOX11 Expression in Routine Lymphoma Tissue Sections: Characterization of New Monoclonal Antibodies for Diagnosis of Mantle Cell Lymphoma , 2014, The American journal of surgical pathology.

[27]  F. Jardin,et al.  Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index , 2014, Genes, chromosomes & cancer.

[28]  A. Salar,et al.  Distinction between Asymptomatic Monoclonal B-cell Lymphocytosis with Cyclin D1 Overexpression and Mantle Cell Lymphoma: From Molecular Profiling to Flow Cytometry , 2013, Clinical Cancer Research.

[29]  T. Haferlach,et al.  SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis , 2013, Leukemia.

[30]  Manel Juan,et al.  Landscape of somatic mutations and clonal evolution in mantle cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[31]  E. Giné,et al.  Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. , 2012, Cancer research.

[32]  B. Sander,et al.  Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. , 2012, Blood.

[33]  E. Giné,et al.  Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease , 2012, Leukemia.

[34]  M. Kaminski,et al.  Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. , 2011, Blood.

[35]  R. Lai,et al.  Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis , 2011, Haematologica.

[36]  B. Sander,et al.  Impact of TP53 mutation and 17p deletion in mantle cell lymphoma , 2011, Leukemia.

[37]  Richard Simon,et al.  Probabilistic classifiers with high-dimensional data. , 2011, Biostatistics.

[38]  J. Leonard,et al.  Is there a role for "watch and wait" in patients with mantle cell lymphoma? , 2011, Seminars in hematology.

[39]  R. Siebert,et al.  Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma , 2010, Genes, chromosomes & cancer.

[40]  Rafael A Irizarry,et al.  Frozen robust multiarray analysis (fRMA). , 2010, Biostatistics.

[41]  A. Rosenwald,et al.  Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. , 2010, Cancer research.

[42]  H. Eve,et al.  Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Jeroen van der Laak,et al.  Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network , 2009, Journal of hematopathology.

[44]  J. Leonard,et al.  Outcome of deferred initial therapy in mantle-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  E. Giné,et al.  Leukemic involvement is a common feature in mantle cell lymphoma , 2007, Cancer.

[46]  D. Catovsky,et al.  A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. , 2003, Blood.

[47]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[48]  A. López-Guillermo,et al.  Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. , 1999, Blood.

[49]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[50]  W. Chan,et al.  p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. , 1996, Blood.

[51]  F. Bosch,et al.  p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. , 1996, Blood.

[52]  E. Campo,et al.  Mantle cell lymphoma: evolving management strategies. , 2015, Blood.

[53]  E. Campo,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[54]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[55]  E. Campo,et al.  Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.